Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.47 |
| ▸ | ASPH | Q12797 | 5/20 | 0.47 |
| ▸ | KDM8 | Q8N371 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | AGER | Q15109 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | MYC | P01106 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6169072 | 0.83 | NOS3 (0.45) | KDM4EASPHKDM8ALDH1A1MAPT | |
| SCHEMBL14284234 | 0.81 | KDM4E (0.46) | KDM4EASPHKDM8ALDH1A1MAPT | |
| SCHEMBL30631992 | 0.81 | NOS3 (0.48) | KDM4ENOS3NOS2KMT2ALMNA | |
| SCHEMBL28313767 | 0.81 | KDM4E (0.46) | KDM4EASPHKDM8ALDH1A1MAPT | |
| SCHEMBL19857487 | 0.81 | KDM4E (0.60) | KDM4EASPHKDM8ALDH1A1MAPT | |
| SCHEMBL1437221 | 0.81 | NOS3 (0.48) | KDM4ENOS3NOS2KMT2ALMNA | |
| SCHEMBL1541111 | 0.81 | KDM4E (0.46) | KDM4EASPHKDM8ALDH1A1MAPT | |
| SCHEMBL30049082 | 0.81 | KDM4E (0.50) | KDM4EASPHKDM8ALDH1A1MAPT | |
| SCHEMBL9684174 | 0.81 | KDM4E (0.50) | KDM4EASPHKDM8ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL16741076 | 0.79 | NOS3 (0.47) | KDM4ENOS3NOS2KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116943617-A | Dimethyl pyridinamine modified nano magnetic bead and preparation method and application thereof | 广东千祺生物科技有限公司 | 2023-10-27 | — | — | CN | claimed |
| CN-110794647-A | Photosensitive resin composition and preparation method thereof | 臻鼎科技股份有限公司 | 2020-02-14 | — | — | CN | claimed |
| EP-0744395-B1 | PROCESS FOR PRODUCING DIMETHYLAMINE | MITSUBISHI RAYON CO (JP) | 2001-10-31 | — | — | EP | claimed |
| EP-3927427-B1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | NIMMUNE BIOPHARMA INC (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-116943617-A | Dimethyl pyridinamine modified nano magnetic bead and preparation method and application thereof | 广东千祺生物科技有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-113748109-B | Lanthionine C-like protein 2 ligands, cells prepared with said ligands and therapies using said ligands | 朗多生物制药股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-109689848-B | Fragrance composition | 奇华顿股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| US-11377437-B2 | Lanthionine C-like protein 2 ligands, cells prepared therewith, and therapies using same | LANDOS BIOPHARMA, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| EP-3927427-A1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | LANDOS BIOPHARMA, INC. (US) | 2021-12-29 | — | — | EP | disclosed |
| CN-113748109-A | Lanthionine C-like protein 2 ligands, cells prepared with said ligands and therapies using said ligands | 朗多生物制药股份有限公司 | 2021-12-03 | — | — | CN | disclosed |
| US-20210355101-A1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | LANDOS BIOPHARMA, INC. (US) | 2021-11-18 | — | — | US | disclosed |
| US-5952532-A | CONTACTING AROMATIC FEEDSTOCK WITH OXIDANT COMPRISING MOLECULAR OXYGEN IN PRESENCE OF A CATALYST COMPRISING A SUPPORT, TRANSITIONAL METALS AND A MULTIDENTATE CHELATING BINUCLEATING LIGAND AS PROMOTER | SUNOCO, INC. (US) | 1999-09-14 | — | — | US | disclosed |
| US-5861536-A | USING A CATALYST COMPRISING A SUPPORT, TRANSITION METAL; AND A MONO- OR BINUCLEATING LIGAND COMPRISING AT LEAST ONE NITRO OR NITROSO GROUP | SUN COMPANY, INC. (R&M) (US) | 1999-01-19 | — | — | US | disclosed |
| US-5741802-A | FOR TREATMENT OF MEMORY LOSS | UNIVERSITY OF FLORIDA (US) | 1998-04-21 | — | — | US | disclosed |
| EP-0659078-A4 | ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM. | UNIV FLORIDA (US) | 1996-04-24 | — | — | EP | disclosed |
| EP-0659078-A1 | ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 1995-06-28 | — | — | EP | disclosed |
| WO-1994005288-A1 | ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM | UNIVERSITY OF FLORIDA (US) | 1994-03-17 | — | — | WO | disclosed |
| US-4104274-A | 1-Substituted-2-(2-pyridinyl)ethanone N-oxides | WARNER-LAMBERT COMPANY (US) | 1978-08-01 | — | — | US | disclosed |
| US-4076720-A | 1-Substituted-2-(2-pyridinyl)ethanone N-oxides | WARNER-LAMBERT COMPANY (US) | 1978-02-28 | — | — | US | disclosed |
| US-4056619-A | 1-Substituted-2-(2-pyridinyl)ethanone N-oxides | WARNER-LAMBERT COMPANY (US) | 1977-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377437-B2 | Lanthionine C-like protein 2 ligands, cells prepared therewith, and therapies using same | LCP2, LANCL2, SSB | KDM4E 3905/4885ASPH 2875/4885KDM8 2239/4885 |
| US-20210355101-A1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | LCP2, LANCL2, SSB | KDM4E 3905/4885ASPH 2875/4885KDM8 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.